Point-of-care diagnostic company Molbio Diagnostics Ltd has raised ₹281.5 crore in anchor funding for its IPO. The healthcare technology firm, which is backed by significant funds from foreign private equity firm Temasek and Motilal Oswal Private Equity, has secured this funding just before the public issue to the general public.

The capital collection indicates significant institutional investor interest in the company’s stocks. The Mnchehmed Mudharru Kassi (MolBio Diagnostics) has obtained anchor funding of ₹281.5 crore. It provides momentum ahead of its public listing on major domestic exchanges.

Anchor allocation and equity pricing

In the official release and a circular uploaded on the website of the stock exchange, MolBio Diagnostics concluded the allotment process to a panel of 33 anchor investors for 34.88 lakh equity shares. The equity listing price at the anchor was ₹807 per share, representing the high end of the company’s IPO price range. 

The primary share price reaction follows the limit for the price when purchasing the anchor allocation, indicating the readiness of capital managers to invest at the company’s peak proposed share price. In the allotment process, the diagnostics platform received ₹281.5 crore in firm commitments prior to retail and non-institutional bidding floors opening.

There was a large supply of active bidders, including a broad range of international and domestic institutional investment companies. Among the leading global fund managers to book securities are WhiteOak Capital, Mirae Asset, HDFC Life Insurance, BlackRock Global Funds, and key domestic insurance companies like Bajaj Life Insurance. 

Domestic asset management firms also showed a high level of conviction in the offering, the major allocators being Nippon India Mutual Fund, ICICI Prudential Mutual Fund, Kotak Mutual Fund, and Tata Mutual Fund. Domestic mutual funds received 23.54 lakh equity shares, accounting for 67.51% of the anchor book in various schemes out of the total number of equity shares issued.

Core operations and capital deployment

The anchor selling is a part of the initial public offering of the medical diagnostics maker Molbio Diagnostics, where it plans to raise ₹904 crore to ₹940 crore in the primary market. The public offering is a new issuance of equity shares that may include an offer for sale, which would allow existing equity holders to sell a portion of their holdings. 

The fresh capital raised by the public issue is to be invested in strengthening the core operational infrastructure. It adds specialized manufacturing equipment for facilities, expansion of production capacity, and funds corporate requirements for long-term growth of the business.

Molbio Diagnostics created a niche in the medical technology industry by developing innovative molecular diagnostic solutions at the point of care. Truenat technology forms the main product of the company. The technology has proved to be fast, decentralized, and cost-effective in diagnosing several diseases, which include infections such as tuberculosis, coronavirus disease, hepatitis, HIV, and HPV.

The technology offers vital information on diagnostics in constrained resources and remote settings to fill critical gaps in health access. Interested responses during the anchor round highlight institutional trust in the company’s technology stack, market positioning, and continued strategy for growth.

Conclusion

The company announced that it had received payments worth ₹281.5 crore from the 33 prominent anchor investors, a step that has taken the company closer to becoming a public entity on the BSE and the NSE.

The company brings strong institutional support to the public market as its anchor investors are global fund managers who had placed a booking for 67.51% of its anchor shares with domestic mutual funds at ₹807 each. The anchor sale enhances the overall anchor sale and is expected to leave the company with enough capital to expand and retool manufacturing plants.